Seres Health Closes $48 Million Series C Financing

CAMBRIDGE, Mass. -- Seres Health, Inc., a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, announced today that it has closed its Series C round with $48 million in new investment.  The proceeds from this financing are planned to be used to advance the development of its lead product candidate, SER-109, for preventing the recurrence of Clostridium difficile infection, into Phase 3 clinical trials and to advance the development of therapeutics to treat other diseases of the human microbiome.

"We are very pleased with the strong interest in this financing round from leading, public healthcare investors, as it further validates the potential of our microbiome therapeutics platform to produce lifesaving therapeutics," said Dr. Roger J. Pomerantz, President, CEO and Chairman of Seres Health. "Expanding our investor base will enable the further strengthening of our pipeline and advancement of multiple programs to the clinic."

Seres Health was founded with initial funding from Flagship Ventures in 2012.

About Seres Health

Seres Health is a clinical-stage therapeutics company focused on discovering and developing Ecobiotic® therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. Founded by the Flagship Ventures innovation foundry, VentureLabs, Seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. Current candidates span infectious, metabolic, and inflammatory diseases. Seres recently announced a research alliance with Mayo Clinic and has received over $65 million in funding to date. For more information, please visitwww.sereshealth.com.

CONTACT: 
For Seres Health: Emily Rossi
Ruder Finn 
212.593.6431
[email protected]  

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.